[Development of a novel cancer cell therapy using enhanced cross-presentation of dendritic cells activated by innate lymphocyte].
Shin-ichiro
S
Fujii
D056704:Adaptive Immunity / Q000276:immunology; D000818:Animals; D017951:Antigen Presentation; D055610:Antigens, CD1d / Q000378:metabolism; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D003713:Dendritic Cells / Q000276:immunology*; D006023:Glycoproteins / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology; D051379:Mice; D055611:Natural Killer T-Cells / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D055610:Antigens, CD1d; D006023:Glycoproteins; D015395:Histocompatibility Antigens Class I